How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco ...

For example, New Yorkers are two times more likely than New Orleanians to name willpower as a reason why they can't lose ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...